Ciproxifan, an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APP Tg2576 mouse model of Alzheimer's disease
about
International Union of Basic and Clinical Pharmacology. XCVIII. Histamine ReceptorsBehavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines.Histamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: relevance to Alzheimer's disease, ADHD, schizophrenia, and drug abuseHistaminergic system in brain disorders: lessons from the translational approach and future perspectives.Impairments in experience-dependent scaling and stability of hippocampal place fields limit spatial learning in a mouse model of Alzheimer's disease.A Comprehensive Behavioral Test Battery to Assess Learning and Memory in 129S6/Tg2576 MiceInhibition of histamine receptor 3 suppresses glioblastoma tumor growth, invasion, and epithelial-to-mesenchymal transition.Transgenic APP expression during postnatal development causes persistent locomotor hyperactivity in the adult.Ciproxifan, a histamine H3 receptor antagonist, reversibly inhibits monoamine oxidase A and B.The histaminergic network in the brain: basic organization and role in disease.Translational Assays for Assessment of Cognition in Rodent Models of Alzheimer's Disease and Dementia.The Histamine H3 Receptor Antagonist E159 Reverses Memory Deficits Induced by Dizocilpine in Passive Avoidance and Novel Object Recognition Paradigm in Rats.The Effect of Subchronic Dosing of Ciproxifan and Clobenpropit on Dopamine and Histamine Levels in Rats.Histamine H3 Receptor Antagonist Prevents Memory Deficits and Synaptic Plasticity Disruption Following Isoflurane Exposure.Ciproxifan, an H3 receptor antagonist, improves short-term recognition memory impaired by isoflurane anesthesia.Knockout of histamine receptor H3 alters adaptation to sudden darkness and monoamine levels in the zebrafish.The Histamine H3 Receptor Antagonist DL77 Ameliorates MK801-Induced Memory Deficits in Rats.
P2860
Q26827568-9F2EB66C-4648-4121-AB99-AB4B3CBD11A4Q26858963-EFB81567-490F-43CA-9F68-BE64E1FA656AQ30462161-298394E6-E6ED-444C-B3E4-BBD9067F0C6DQ34568925-F0052C2C-50BC-4234-B731-BC9CD315BC44Q35684738-AC041929-ACB2-4AB8-9DFD-D4A07D9953E2Q35903525-5777C752-4265-43B3-844E-4A0656F2FD28Q36231984-A0553E71-D696-4C30-B060-46B2CE1BCEF9Q36278646-1B5E2A5A-95CF-4CFE-95E0-1D134F5FD711Q37584491-4E36D5B4-BF7E-4C3A-8598-6AAF2DEA984AQ38115678-697343E4-AAF6-4D41-851C-4ECAE318DF0CQ38956724-CF68D763-23AD-4C6C-A3E6-6834028692FEQ42691812-AEABAB5C-EFAC-4B7B-84E9-BA66F312F03CQ43011663-A218FC22-7696-4DFD-88B0-2D2BC6F1C7B5Q47333717-0BB14764-FF91-43FF-8D3A-29EFD5149C01Q47429533-E4D193BB-F6BB-45B6-9AA6-538AE079B339Q47650234-E69B922A-90FD-4412-8CFE-6476FD6F3035Q50421768-FA2FC53A-406C-42AF-A315-2F792E46C1E9
P2860
Ciproxifan, an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APP Tg2576 mouse model of Alzheimer's disease
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Ciproxifan, an H3 receptor ant ...... e model of Alzheimer's disease
@ast
Ciproxifan, an H3 receptor ant ...... e model of Alzheimer's disease
@en
Ciproxifan, an H3 receptor ant ...... e model of Alzheimer's disease
@nl
type
label
Ciproxifan, an H3 receptor ant ...... e model of Alzheimer's disease
@ast
Ciproxifan, an H3 receptor ant ...... e model of Alzheimer's disease
@en
Ciproxifan, an H3 receptor ant ...... e model of Alzheimer's disease
@nl
prefLabel
Ciproxifan, an H3 receptor ant ...... e model of Alzheimer's disease
@ast
Ciproxifan, an H3 receptor ant ...... e model of Alzheimer's disease
@en
Ciproxifan, an H3 receptor ant ...... e model of Alzheimer's disease
@nl
P2093
P2860
P1476
Ciproxifan, an H3 receptor ant ...... e model of Alzheimer's disease
@en
P2093
Mark E Bardgett
Molly S Griffith
Natasha N Davis
Patrick J Schultheis
P2860
P356
10.1016/J.NLM.2010.10.008
P577
2010-11-10T00:00:00Z